GlassScriptPhysician profile
Anton Furman
NPI 1699167163
$2,433.23
in general payments reported to CMS, 2019-2025
28 companies · $829 in 2025
The $829 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.10 · 2020: $34.28 · 2021: $177 · 2022: $110 · 2023: $534 · 2024: $722 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,084.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $350.13 | 2023-2025 | Rexulti, Nuedexta |
| Sumitomo Pharma America, INC. | $279.88 | 2023-2025 | Gemtesa |
| Acadia Pharmaceuticals INC | $237.44 | 2023-2025 | Nuplazid |
| Abbvie INC. | $195.37 | 2021-2025 | |
| Lundbeck LLC | $173.64 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $144.02 | 2021-2025 | Zepbound, Mounjaro, Amyvid |
| Neurocrine Biosciences, INC. | $139.16 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.97 | 2023-2025 | Caplyta |
| Pfizer INC. | $129.19 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $105.39 | 2020-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $75.23 | 2024-2025 | Austedo Xr, Austedo Xr |
| Exact Sciences Corporation | $51.02 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $47.01 | 2021-2022 | |
| Astellas Pharma US INC | $46.92 | 2022-2025 | Veozah |
| Scilex Pharmaceuticals INC. | $42.64 | 2023-2024 | Ztlido |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $41.84 | 2023-2024 | |
| Axsome Therapeutics, INC. | $41.74 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $30.16 | 2024-2025 | Trelegy Ellipta |
| Mylan Specialty L.P. | $29.37 | 2022-2024 | Yupelri |
| Novo Nordisk INC | $28.99 | 2019-2021 | |
| Eisai INC. | $16.93 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.62 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.86 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.76 | 2024 | Voquezna |
| Amarin Pharma, INC. | $12.92 | 2021 | |
| Merck Sharp & Dohme LLC | $12.83 | 2022 | |
| Allergan, INC. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anton Furman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.